First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors

Summary

TP-0184 is a potent inhibitor of ALK2 or ACRV1 kinase, a constitutively active serine/threonine receptor kinase due to activating mutations or upregulated upstream signaling pathways. This is a Phase 1, open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-0184 administered once weekly for 4 weeks in patients with advanced solid tumors.

Timeline

Start

2018-07-10

Primary completion

2021-03-08

Completion

2021-03-08

Drugs

Indications